The ACR have published their first guideline for the management of large vessel vasculitis, which covers giant cell arteritis and Takayasu arteritis. The new guideline differs from the current EULAR recommendations on some important points, but do these different views actually affect patient care?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Maz, M. et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 73, 1349–1365 (2021).
Hellmich, B. et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 79, 19–30 (2020).
Dejaco, C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann. Rheum. Dis. 77, 636–643 (2018).
Monti, S. et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5, e001003 (2019).
Duftner, C. et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 4, e000612 (2018).
Dua, A. B. et al. Giant cell arteritis: a systematic review and meta-analysis of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol. 3, 429–441 (2021).
Yates, M. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 75, 1583–1594 (2016).
Labarca, C. et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology 55, 347–356 (2016).
Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.H. declares receiving speaker fees and/or consultancy fees from Abbvie, AstraZeneca, Chugai, Novartis and Roche, and was convenor of the 2018 EULAR recommendations and the 2020 Deutsche Gesellschaft für Rheumatologie guideline for the management of large vessel vasculitis. F.B. declares receiving consultancy fees, honoraria and travel expenses from Galapagos, Horizon Therapeutics, Roche and Sanofi, and grant support from Horizon Therapeutics, Mundipharma, Roche and Sanofi. He has served as co-principal investigator and site investigator in a Mundipharma sponsored trial in polymyalgia rheumatica, and as principal investigator and site investigator in giant cell arteritis and polymyalgia rheumatica trials sponsored by Sanofi.
Supplementary information
Rights and permissions
About this article
Cite this article
Hellmich, B., Buttgereit, F. GCA management guidelines — vive la différence?. Nat Rev Rheumatol 17, 649–650 (2021). https://doi.org/10.1038/s41584-021-00686-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-021-00686-z
This article is cited by
-
Biologika bei Kollagenosen und Vaskulitiden
Der Internist (2022)